Dr. Esther H. Rehmus, MD | Akron, OH ...

Dr. Esther H. Rehmus

Claim this profile

Cleveland Clinic Akron General

Studies Breast Cancer
Studies Breast cancer
12 reported clinical trials
28 drugs studied

Area of expertise

1

Breast Cancer

Esther H. Rehmus has run 5 trials for Breast Cancer. Some of their research focus areas include:

Stage I
Stage II
HER2 positive
2

Breast Cancer

Esther H. Rehmus has run 5 trials for Breast cancer. Some of their research focus areas include:

Stage I
Stage II
HER2 positive

Affiliated Hospitals

Image of trial facility.

Cleveland Clinic Akron General

Clinical Trials Esther H. Rehmus is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

More about Esther H. Rehmus

Clinical Trial Related

11 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Esther H. Rehmus has experience with

  • Paclitaxel
  • Carboplatin
  • Biospecimen Collection
  • Docetaxel
  • Duloxetine
  • Crizotinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Esther H. Rehmus specialize in?

Is Esther H. Rehmus currently recruiting for clinical trials?

Are there any treatments that Esther H. Rehmus has studied deeply?

What is the best way to schedule an appointment with Esther H. Rehmus?

What is the office address of Esther H. Rehmus?

Is there any support for travel costs?